$AORT News

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

Below Expected Sales for AMDS Hurt Artivion (AORT) in Q2

Needham Reiterates Buy on Artivion, Maintains $44 Price Target

3 Reasons to Sell AORT and 1 Stock to Buy Instead

Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion

Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

Artivion Says FDA Approves Premarket Approval Application For AMDS Hybrid Prosthesis

What Artivion (AORT)'s Strong Q1 Growth But Lowered Guidance Means For Shareholders

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks

Artivion (NYSE:AORT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Artivion Bets On Full Aortic Arch Suite After Endospan Deal

Artivion closes Endospan buyout to acquire recently approved heart device

Artivion strengthens aortic arch portfolio with $135m Endospan acquisition

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion Completes Acquisition of Endospan Ltd.

5 Insightful Analyst Questions From Artivion’s Q1 Earnings Call

Artivion Inc (NYSE:AORT) Catches the GARP Eye With Affordable Growth Screen

Artivion (AORT) Price Target Decreased by 16.86% to 43.73